MAYNE PHARMA GROUP LIMITED — Director's Dealing 2016

Dec 27, 2016

Appendix 3Y Change of Director’s Interest Notice

**Appendix

3Y**

Rule 3.19A.2

**Change

of Director’s Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nancy Dolan
Date of last notice	18 December 2016

Part 1 -­‐ Change of director’s relevant interests in securities

_In

the case of a trust, this includes interests in the trust made available by the responsible entity of the trust_

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Direct or indirect interest	Indirect interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevant	J Bennett & N Dolan <Bennett-Dolan Family S/FA/C>
interest.
Date of change	19 December 2016
No. of securities held prior to change	43,155 Ordinary Fully Paid Shares
Class	Ordinary fully paid shares
Number acquired	31,345 Ordinary Fully Paid Shares
Number disposed	Nil
Value/Consideration	$40,136.57
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	74,500 Ordinary Fully Paid Shares
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue of	On-market trade
securities under dividend reinvestment plan, participation in buy-back

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

**Part

2 – Change of director’s interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to which the interest haschanged
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation
Interest after change

**Part

3 –**[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts	No
detailed above traded during a+closed periodwhereprior written clearance was required?
If so, was prior written clearance provided toallow the trade toproceed during thisperiod?	N/A
If prior written clearance was provided, onwhat date was thisprovided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011